- Home
- » CME / CE Programs
- » Biologic Bulletins
- » Advancing the Art and Science of Psoriasis and Psoriatic Arthritis Management
Advancing the Art and Science of Psoriasis and Psoriatic Arthritis Management
Release date: December 2011
Expiration date: December 31, 2012
Estimated time to complete activity: 1 hour
This educational initiative is provided by Curatio CME Institute, the University of Chicago, the Dermatology Nurses’ Association, and the Society of Dermatology Physician Assistants. This activity has been created in collaboration with the National Psoriasis Foundation and the International Psoriasis Council.
Support for this activity has been provided through educational grants from Abbott and Janssen.
Activity Overview
Effective management of psoriasis and psoriatic arthritis must take individual patient characteristics, comorbid diseases, access to treatment, and disease severity—as well as patient preferences—into consideration. This Biologic Bulletin reviews safety issues and efficacy data for traditional systemic therapies and biologic agents based on guidelines from the American Academy of Dermatology.
Target Audience
This educational activity has been designed to meet the current educational needs of dermatologists, dermatology nurses, nurse practitioners, physician assistants, and other health care professionals involved in the care of patients with moderate to severe psoriasis or psoriatic arthritis.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Outline appropriate, individualized treatment strategies in accordance with evidence-based recommendations
- Integrate into practice strategies for managing safety-related issues in patients receiving long-term therapy with traditional and biologic systemic agents
- Evaluate evidence-based data for new therapies used to treat psoriasis and psoriatic arthritis
- Distinguish comorbid conditions that can affect the treatment of patients with moderate to severe psoriasis or with psoriatic arthritis
- Implement strategies for managing a diverse set of patients with psoriasis that include consideration of comorbid disease and concomitant conditions
Steering Committee
Alan Menter, MD—Program Chair
Jerry Bagel, MD
Kenneth B. Gordon, MD
Kristine Kucera, DHS, MPAS, PA-C
Melodie Young, MSN, RN, A/GNP-C
Editors
Jerry Bagel, MD
Director, Psoriasis Treatment Center of Central New Jersey
Clinical Associate Professor of Dermatology
College of Physicians & Surgeons of Columbia University
New York, New York
Kristine Kucera, DHS, MPAS, PA-C
Adjunct Clinical Professor
University of Texas Southwestern Medical Center
Physician Assistant
Dermatology Center of Frisco
Dallas, Texas
Author
Curatio CME Institute
Accreditation
Physicians, Physician Assistants, and Nurse Practitioners
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of Physician Assistants and the American Academy of Nurse Practitioners accept certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
Nurses
The Dermatology Nurses’ Association (DNA) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
Provider approved by the California Board of Registered Nursing (CBRN), Provider Number CEP5708. Accreditation refers to educational content only and does not imply ANCC, CBRN, or DNA endorsement of any product or service.
Method of Participation
There are no fees for participating in this CME/CE activity. To receive credit during the period December 2011 to December 31, 2012, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, (3) complete the posttest and activity evaluation, including the certificate information section, and (4) achieve a score of at least 70% on the posttest.
The posttest can be accessed at the end of the activity. Please e-mail any questions to cmeinfo@curatiocme.com.
Media
The Internet and a print publication were selected as the instructional formats to accommodate the learning preferences of a significant portion of the target audience.
Disclosure
In accordance with the ACCME Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of everyone in a position to control content of an educational activity. A relevant financial relationship is a relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears below:
Jerry Bagel, MD, has disclosed the following relevant financial relationships:
| Speaker, Clinical Trial: | Abbott, Amgen, Janssen, LEO Pharma |
Dr. Bagel discusses the unlabeled or investigational use of a commercial product.
Kenneth B. Gordon, MD, has disclosed the following relevant financial relationships:
| Consultant/Investigator: | Abbott, Amgen, Centocor Ortho Biotech |
| Consultant: | Lilly, Merck, Novartis, Pfizer |
Kristine Kucera, DHS, MPAS, PA-C, has disclosed the following relevant financial relationships:
| Speaker: | Abbott, Amgen, Centocor Ortho Biotech, Warner Chilcott |
| Editorial Board and Author: | Educational Awareness Solutions |
Ms. Kucera discusses the unlabeled or investigational use of a commercial product.
Alan Menter, MD, has disclosed the following relevant financial relationships:
| Advisory Board/Speaker: | Abbott, Amgen, Astellas, Centocor Ortho Biotech, Galderma, Genentech, Warner Chilcott, Wyeth |
| Consultant: | Abbott, Amgen, Astellas, Centocor Ortho Biotech, Eli Lilly, Galderma, Genentech, Stiefel, Warner Chilcott, Wyeth |
| Investigator: | Abbott, Allergan, Amgen, Astellas, Asubio, Celgene, Centocor Ortho Biotech, DUSA, Eli Lilly, Genentech, Novartis, Novo Nordisk, Pfizer, Promius, Stiefel, Syntrix Biosystems, Warner Chilcott, Wyeth |
Melodie Young, MSN, RN, A/GNP-C, has disclosed the following relevant financial relationships:
| Consultant: | Janssen, Ortho |
| Speaker: | Abbott, Centocor Ortho Biotech |
| Subinvestigator: | Celgene |
Curatio CME Institute
The employees of Curatio CME Institute have disclosed no relevant financial relationships.
University of Chicago Center for Continuing Medical Education
The employees of the Center for Continuing Medical Education have disclosed no relevant financial relationships.
Dermatology Nurses’ Association
The management and contractors of the Dermatology Nurses’ Association have disclosed no relevant financial relationships.
Society of Dermatology Physician Assistants
The employees of the Society of Dermatology Physician Assistants have disclosed no relevant financial relationships.
National Psoriasis Foundation
The employees of the National Psoriasis Foundation have disclosed no relevant financial relationships.
International Psoriasis Council
Paul Tebbey, PhD, has disclosed the following relevant financial relationships:
| Consultant: | Incyte Pharmaceuticals |
| Employee: | Baxter Healthcare |
Disclaimer
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition.
Unapproved Product Use
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Curatio CME Institute, the University of Chicago, the Dermatology Nurses’ Association, the Society of Dermatology Physician
Assistants, the National Psoriasis Foundation, the International Psoriasis Council, Abbott, and Janssen do not recommend the use of any agent outside the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not represent the views of Curatio CME Institute, the University of Chicago, the Dermatology Nurses’ Association, the Society of Dermatology Physician Assistants, the National Psoriasis Foundation, the International Psoriasis Council, Abbott, or Janssen. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
| Generic Name | Trade Name | Approved Use (if any) | Unapproved/Investigational Use |
| Acitretin | Soriatane | Treatment of adult patients with severe psoriasis | Use in combination with narrowband UVB phototherapy |
| Adalimumab | Humira | Treatment of adults with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate | Investigational use as treatment for children and adolescents with psoriasis |
| Alefacept | Amevive | Treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy | Investigational use as treatment for children and adolescents with psoriasis |
| Etanercept | Enbrel | Treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy | Investigational use as treatment for children and adolescents with psoriasis |
| Methotrexate | Rheumatrex | Symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy | Investigational use as treatment for children and adolescents with psoriasis |
| Pimecrolimus | Elidel | Second-line therapy for the short-term and noncontinuous chronic treatment of mild to moderate atopic dermatitis in nonimmunocompromised adults and children 2 years of age and older who have not responded adequately to other topical prescription treatments or in whom those treatments are not advisable | Treatment of psoriasis |
| Tacrolimus ointment | Protopic | Second-line therapy for the short-term and noncontinuous chronic treatment of moderate to severe atopic dermatitis in nonimmunocompromised adults and children who have not responded adequately to other topical prescription treatments for atopic dermatitis or in whom those treatments are not advisable | Treatment of psoriasis |
| Ustekinumab | Stelara | Treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy | Treatment of psoriatic arthritis; use in combination with methotrexate for the treatment of psoriatic arthritis Investigational use as treatment for children and adolescents with psoriasis |
Hardware/Software Requirements
- JavaScript enabled browser
- Adobe Flash Player plugin v.8.0+
Contact Information
PsoriasisTx.com
100 Campbell Boulevard
Suite 103
Exton, PA 19341
editor@psoriasistx.com
Policy on Privacy and Confidentiality
Curatio CME Institute makes every effort to protect the privacy of PsoriasisTx.com users; user information is used only to maintain records as required by the American Medical Association (AMA) and the ACCME.
Curatio CME Institute does not require individuals to register to use PsoriasisTx.com; registration is only required for physicians, health care professionals, and other users to participate in and receive CME/CE credit for accredited educational programs hosted on PsoriasisTx.com
Curatio CME Institute is required by the AMA and the ACCME (and occasionally by other accrediting organizations) to collect user information that will allow Curatio CME Institute to issue a CME/CE certificate. Curatio CME Institute is required to keep this information on file for up to 6 years. The information is stored in a secure database and used only to verify individual participation in a CME/CE activity and to reissue a certificate if a user's original certificate is lost or misplaced.
Information gathered through PsoriasisTx.com will not be released to any other company or organization for any purpose; this information remains confidential.
Curatio CME Institute uses Web site tracking software to determine how PsoriasisTx.com is used. This information helps Curatio CME Insitute determine the best strategies for improving PsoriasisTx.com and better meeting the needs of its users. This software does not identify individual users.
If you have any questions about PsoriasisTx.com or any Curatio CME Institute policies, you may contact us at info@psoriasistx.com.
Thank you for using PsoriasisTx.com.
